The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis
Files
Publication date
2022-05-24
Authors
Salmon, Kristiana
Kiernan, Matthew C
Kim, Seung H
Andersen, Peter M
Chio, Adriano
van den Berg, Leonard
Van Damme, Philip
Al-Chalabi, Ammar
Lillo, Patricia
Andrews, Jinsy A
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
cc_by_nc
Abstract
Several genetically-targeted therapies are being developed for ALS. Research is increasingly supportive of a greater incidence of clinically actionable variants in sporadic ALS than previously reported. Salmon et al. outline the need to improve access, and offer genetic testing to all people diagnosed with ALS.
Keywords
Amyotrophic Lateral Sclerosis/diagnosis, Genetic Testing, Humans, Mutation/genetics, General Medicine, Journal Article
Citation
Salmon, K, Kiernan, M C, Kim, S H, Andersen, P M, Chio, A, van den Berg, L H, Van Damme, P, Al-Chalabi, A, Lillo, P, Andrews, J A & Genge, A 2022, 'The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis', Brain : a journal of neurology, vol. 145, no. 4, pp. 1207-1210. https://doi.org/10.1093/brain/awab472